Discover investment opportunities in Vital Pharmaceuticals Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Vital Pharmaceuticals Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Vital Pharmaceuticals Stocks using our Smart AI Filter.
8 stocks found for "Vital Pharmaceuticals Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.85 | ±33.0% | 14.9 | 3.20% | |||
0.53 | ±27.3% | 8.3 | 3.85% | |||
0.77 | ±72.1% | 47.5 | 0.00% | |||
0.28 | ±24.8% | 33.7 | 0.00% | |||
0.64 | ±32.6% | 17.0 | 0.00% | |||
0.35 | ±16.4% | 24.0 | 2.86% | |||
0.43 | ±28.2% | 15.2 | 1.20% | |||
0.34 | ±26.9% | 22.8 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What factors contribute to Pfizer’s (PFE) growth outlook?
A: Pfizer's growth is driven by its strong pipeline of vaccines and treatments, including its COVID-19 vaccine. The company also benefits from strategic acquisitions and collaborations. However, patent expirations could impact future revenue.
Q: How does Johnson & Johnson’s (JNJ) product diversification mitigate risk?
A: Johnson & Johnson's diverse portfolio across pharmaceuticals, medical devices, and consumer health products provides stability, reducing dependency on any single product line or market segment against economic downturns.
Q: Why might investors consider Merck (MRK) for long-term stability?
A: Merck's consistent revenue from its key drugs, such as Keytruda, along with a robust pipeline of new products, offers potential for steady growth, appealing to long-term investors seeking stable returns.
Q: What makes AbbVie (ABBV) attractive for income-focused investors?
A: AbbVie offers an attractive dividend yield, bolstered by strong earnings from its immunology and oncology product lines. Long-term growth could further support consistent dividend payouts.
Q: How does Bristol-Myers Squibb (BMY) balance risk and growth?
A: Bristol-Myers Squibb balances risk through a mix of established drugs and a promising pipeline, particularly in oncology and cardiovascular treatments, supporting both current revenue and future expansion potential.
Q: Why has Eli Lilly (LLY) been experiencing recent growth?
A: Eli Lilly's growth is largely due to its leading diabetes treatments and new drug approvals, bolstered by innovations in oncology and neuroscience, which have driven revenue gains.
Molson Coors Beverage has been named as a Top 25 dividend stock, according the most recent Dividend Channel 'DividendRank' report. The report noted that among the coverage universe, TAP shares displayed both attractive valuation metrics and strong profitability metrics.
Read more